Single ascending dose study of the safety, tolerability, and pharmacokinetics of LXR-623 administered orally to healthy Japanese male subjects.
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2007
At a glance
- Drugs LXR 623 (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions
- Sponsors Wyeth
- 20 Sep 2007 In September 2007, Wyeth discontinued development of LXR 623, as it had an unfavourable proflie for further development.
- 20 Sep 2007 Status change from recruiting to discontinued
- 22 Mar 2007 New trial record.